The following provides a brief summary of some notable trends in the latest cancer data. More comprehensive data is available throughout the Cancer data in Australia report for the cancers summarised as well as many other cancers.
2025
FDA Grants Breakthrough Therapy Designation to Darovasertib in Melanoma
A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal melanoma.
Refining Melanoma Treatment With Biomarker-Driven Insights
Welcome back to the second episode of this discussion about biomarkers. The last time we were together, we discussed sensitivity and specificity and the importance of these two aspects in terms of biomarkers in melanoma. We also discussed what kind of characteristics an ideal biomarker would have [in order] for us to use it in a clinical practice.
Ipilimumab plus nivolumab ‘considered a cure’ long term for melanoma brain metastasis
The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.